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Abstract 
 
Robustaflavone derivatives have cytotoxic effect on cancer cell. Inhibition of PI3K on cancer 
cell has correlation with apoptotic induction. The aim of this research is to observe interaction 
from robustaflavone derivatives on PI3K receptor that may give contribution to the cytotoxic 
effect of the compounds on cancer cell line. Geometric optimization of robustaflavone derivatives 
structured was done used Hyperchem 7.5 software. Arguslab 4.01 software with GAdock 
method applied for the docking step. The docking result showed that robustaflavone 7,4',7''- 
trimethyl ether (RTE) has affinity on PI3K target receptor which gave the lowest Gibbs free 
energy (∆G -10,855 kcal/mol). 
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INTRODUCTION 
 
Phosphatidylinositol-3-kinase (PI3K) has 
been known as an important growth and survival 
pathway of the cell, and pathway activation is 
frequently found in human cancers (1). A key 
downstream effector of PI3K is the serine-
threonine kinase Akt which in response to PI3K-
activation, phosphorylates and regulates the 
activity of a number of targets including kinases, 
transcription factors and other regulatory 
molecules. Akt is one kinase responsible to 
inactivate Bad, one of proapoptotic protein, 
through phosphorylation. Akt activation has also 
been shown to activate NF-κB–mediated 
transcription. Activation of NF-κB can suppress 
apoptosis through induction of antiapoptotic 
proteins (2). The PI3K pathway plays a critical 
role in regulating apoptosis, which is induced by 
many chemotherapeutic agents (3). 
Many studies report that plant-compounds 
are potential for oncogene-negative regulator and 
tumor suppressor gene-positive regulator, which 
mean that those are potential as anticancer (4). 
Selaginella doederleinii Hieron (SD) is one of 
Indonesian plant (5) that has antiproliferative 
effect on cancer cell and antiviral activity (6,7,8,9). 
The SD-compounds that have been known are 
biflavonoid (2,2'',3,3''-tetrahydrorobustaflavone 
7,4',7''-trimethyl ether, robustaflavone 7,4',7''- 
trimethyl ether, robustaflavone 4'-methyl ether, 
amentoflavone derivatives), alkaloid, and lignan 
(8,10,11). The SD-robustaflavone derivatives are 
biapigenin which have cytotoxic effect on cancer 
cells (8). Apigenin is a flavonoid that decreased 
cell survival and apoptosis through 
dephosphorylation of Akt resulted in inhibition of 
its kinase activity, which was followed by reduced 
phosphorylation of proapoptotic proteins BAD 
(12).  
Fisetin is a tetrahydroxyflavone that induce 
apoptosis through inhibition of 
phosphatidylinositol 3-kinase and phosphorylation 
of Akt at Ser
473
 and Thr
308
 (13). The aim of this 
research is to observe affinity and interaction from 
robustaflavone derivatives on PI3K receptor that 
may give contribution to the cytotoxic effect on 
cancer cell line. 
 
MATERIALS AND METHODS 
 
Docking 
In the present work, all the ligands used 
were performed with HyperChem
 
7.0 for Windows 
Molecular Modeling System. Before the docking 
calculation of the ligands, the structures were fully 
optimized. Argus Lab 4.0 with GAdock method 
and rigid ligand was used to perform all the 
docking techniques.  
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The crystal structure of PI3K used for the present 
study was found as complex with inhibitor 
staurosprorine (crystal structure was downloaded 
from Protein Data Bank (1E8Z) as PDB files).  
The whole procedure of docking was 
repeated in three replications. Concluding docking 
results were parameterized in terms of docking 
score (Gibbs free energy/∆G) in kcal/mol. 
 
RESULTS AND DISCUSSION 
 
Docking of robustaflavone derivatives-
PI3K reseptor 
This study presented ligand-receptor 
interaction assay by ArgusLab docking. On the 
first study, PI3K-Quercetin (pdb code: 1E8W) 
would be choosen as a model because quercetin 
and robustaflavone are flavonoid. Nevertheles, 
this model is invalid to be used because the 
method validation showed that the RMSD value 
> 2 with both of ArgusDock and GADock 
methods. Then, the chosen one is PI3K-
Staurosporin (pdb code: 1E8Z) which the RMSD 
value on the method validation < 2. The 
staurosporin binding site on PI3K receptor (Fig. 
4B) is similar with quercetin binding site on 
PI3K receptor. Staurosporin is an alkaloid that 
induces apoptosis through inhibition of protein 
kinase. The result of method validation on 
protein with pdb code 1E8Z showed that the 
lowest Gibbs energy (∆G) is AGDock-rigid, 
followed by GADock-flexible, GADock-rigid, 
and AGDock-flexible with ∆G values are -
12,020; -11,909; -11,644; and -11,426 kcal/mol 
respectively. All of the methods are valid 
because RMSD value from the four methods are 
less than 2 (RMSD <2).  
Figure 1. Structure of S. doederleinii biflavonoid compounds (8). (1) 2,2',3,3'-tetrahydrorobustaflavone 
7,4',7'-trimethyl ether (ThRTE); (2) Robustaflavone 7,4',7'-trimethyl ether (RTE); (3) 
robustaflavone 4'-methyl ether (RME). 
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Three compounds from robustaflavone 
derivatives (Fig. 3) that to be used as ligands, ie 
2,2',3,3'-tetrahydrorobustaflavone 7,4',7'-
trimethyl ether (ThRTE), robustaflavone 7,4',7'-
trimethyl ether (RTE), and robustaflavone 4'-
methyl ether (RME) have been optimized  
The previously with Hyperchem geometry 
optimization. The robustaflavone derivatives 
were interacted on the PI3K receptor at 
staurosporin-binding site (Fig. 4). The first 
chosen method that to be used is AGDock-rigid, 
followed by GADock-flexible, GADock-rigid, 
and AGDock-flexible. Because of failure on the 
docking result when docking of PI3K-ligands 
was done with AGDock-rigid and GADock 
flexible, the next docking of PI3K-ligands was 
done with GADock-rigid. 
The results showed that RTE has the 
lowest energy and followed by ThRTE and RME 
with docking score (∆G) are -10.855 kcal/mol, -
10.628 kcal/mol and -9.686 kcal/mol 
respectively (Table I). The RTE and ThRTE 
docking scores are almost similar and have 
lower energy than RME. It was the same results 
with IC50 values (Table I), which RTE has the 
lowest IC50, followed by ThRTE, and RME. 
amount of hydrogen bond (H-bond) from the 
ligand-PI3K interaction (Table 1) was not 
affected to ∆G score. Its mean that ∆G score 
from ligand-PI3K interaction was not only 
depend on H-bond. Nevertheles, the bonding of 
ligand on the specific amino acid on PI3K 
receptor through hydrogen bond was affected to 
∆G score. The lowest energy of RTE is affected 
by its bonding on Lys
833
 on ATP-binding site of 
PI3K receptor. Mechanism of PI3K inhibition by 
LY294002, a PI3K inhibitor, was also shown to 
involve covalent attack of Lys
833
 and Val 
822 
within the ATP-binding site of PI3K at an 
electrophilic site on the compound (14). Similar 
Figure 2.  Experimental ligand and its bounded to PI3K reseptor (19) was downloaded from 
www.rcsb.org/pdb/ (pdb: 1E8Z). A. PI3K (3D) protein reseptor; B. interaction of 
staurosporin (experimental ligand) on PI3K receptor. 
Figure 3. Interaction of robustaflavone derivatives on PI3K receptor. A. PI3K-RME; B. PI3K-RTE; C. 
PI3K-ThRTE. 
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with Knight and Shokat description (14), the 
mechanism of RTE-PI3K interaction was that 
the oxygen atom of RTE binds to Lys
833 
through 
hydrogen bond and makes extensive 
hydrophobic interactions with residues that form 
the top and bottom of the ATP-binding pocket. 
According to the results, RTE can be candidate 
for PI3K inhibitor.  
Recent studies indicate that numerous 
components of the PI3K/AKT pathway are 
targeted by amplification, mutation and 
translocation more frequently than any other 
pathway in cancer patients, with resultant 
activation of the pathway. This warrants 
exploiting the PI3K/AKT pathway for cancer 
drug discovery (15). Quercetin, luteolin, and 
ursolic acid are potent inhibitors of proliferation 
and inducers of apoptosis on many cancer cells 
through PI3K pathway (16, 17). Isoginkgetin, a 
biflavonoid from Metasequoia glyptostroboides, 
inhibited HT1080 tumor cell invasion. 
Isoginkgetin regulated MMP-9 production via 
PI3K/Akt/NF-KB pathway, as evidenced by the 
findings that isoginkgetin inhibited activities of 
both Akt and NF-KB (18). The cytotoxic 
activities of robustaflavone derivatives, 
biflavonoid compound in Selaginella 
doederleinii Hieron, possibly mediated by PI3K 
inhibition. The cytotoxic effect of robustaflavone 
derivatives on cancer cells promise the future 
research about cell cycle inhibition or apoptosis 
mechanism mediated the cytotoxic effect. 
 
Table I. Docking result and IC50 value of robustaflavone derivatives 
No Ligand 
Docking 
score 
(∆G) 
kcal/mol 
H-
bonds  
Hydrogen bond lengths and 
residues 
IC50 (µM) *) 
HCT 
116 
NCI-
H358 
K562 
1. 
Staurosporin 
(experimental ligand) 
 
 
 
-10.711 1 
Atom N in residue 882 Val 
with atom O ketone  on the 
ligand : 2.707 Ǻ 
-   
2. 
,2',3,3'-
tetrahydrorobustafla
vone 7,4',7'-
trimethyl ether 
(ThRTE)  
 
 
 
-10.628 3 
Atom N in residue 890 Lys 
with O number 13874 on the 
ligand: 2.9 Ǻ 
Atom N in residue 802 Lys 
with O number 13877 on the 
ligand: 2.66 Ǻ 
Atom S in residue 869 Cys with 
O number 13903 on the ligand: 
2.25 Ǻ 
19.1 23.5 28.8 
3. 
Robustaflavone 
7,4',7'-trimethyl 
ether (RTE) 
 
 
-10.855 7 
Atom N in residue 964 Asp 
with O number 13877 on the 
ligand: 2.95 Ǻ 
Atom O in residue 867 Tyr 
with O number 13877 on the 
ligand: 1.92 Ǻ 
Atom N in residue 833 Lys 
with O number 13876 on the 
ligand: 2.5 Ǻ 
Atom N in residue 805 Ala 
with O number 13894 on the 
ligand: 2.7 Ǻ 
Atom O in residue 758 Asp 
with O number 13905 on the 
ligand: 2.56 Ǻ 
Atom O in residue 806 Ser 
with O number 13902 on the 
15.6 20.1 22.5 
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ligand: 2.77 Ǻ 
Atom N in residue 890 Lys 
with O number 13903 on the 
ligand: 2.89 Ǻ 
4. 
Robustaflavone 4'-
methyl ether (RME) 
 
 
-9.686 3 
Atom O in residue 887 Thr 
with O number 13905 on the 
ligand: 2.8 Ǻ 
Atom O in residue 868 Gly 
with O number 13904 on the 
ligand: 2.75 Ǻ 
Atom O in residue 894 Ser 
with O number 13902 on the 
ligand: 2.34 Ǻ 
>100 >100 >100 
 
 
 
 
 
CONCLUSION 
 
The cytotoxic activity of robustaflavone 
derivatives on cancer cell line can be related to 
the affinity and interaction of the compounds on 
PI3K receptor. 
 
ACKNOWLEDGEMENT 
 
This work was supported by The Project 
of Kompetitif LIPI 2010 and all of the members 
of the project. 
 
REFERENCES 
 
Brachmann, S.M., Hofmann, I., Schnell, C., 
Fritsch, C., Wee, S., Lane, H., Wang, S., 
Garcia-Echeverria, C. and Maira, S., 
2009, Specific apoptosis induction by 
the dual PI3K/mTor inhibitor NVP-
BEZ235 in HER2 amplified and PIK3CA 
mutant breast cancer cells, PNAS, 
106(52), 22299-22304. 
Thompson, J.E. and Thompson, C.B., 2004, 
Putting the Rap on Akt, J. Clin. Oncol., 
22(20), 4217-4226. 
Lu, Y., Wang, H. and Mills, G.B., 2003, Targeting 
PI3K-Akt Pathway For Cancer Therapy, 
Rev Clin Exp Hematol, 7(2), 205-228. 
Cardenas, M.E., Sanfridson, A., Cutler, N.S. and 
Heitman, J., 1998, Signal Transduction 
Cascade as Targets for Therapeutic 
Intervention by Natural Products, 
TIBTECH, 16, 427-433. 
Dalimartha, S., 1999, Atlas Tumbuhan Obat 
Indonesia, Jilid 1, Trubus Agriwidya, 
Jakarta, 29-31. 
Silva, G.L., Chai, H., Gupta, M.P., Farnsworth, 
N.R., Cordell, G.A., Pezzuto, J.M., 
Beecher, C.W.W. and Kinghorn, A.D., 
1995, Cytotoxic biflavonoids from 
Selaginella willdenowii, Phytochemistry, 
40(1), 129-134. 
Ma, S., But, P.P., Ooi, V.E., He., Y., Lee, S.H., 
Lee, S. and Lin, R., 2001, Antiviral 
Amentoflavone from Selaginella sinensis, 
Biol. Pharm. Bull., 24(3), 311-312. 
Lee, N.Y., Min, H.Y., Lee, J., Nam, J.W., Lee, Y.J., 
Han, A.R., Wiryawan, A., Suprapto, W., 
Lee, S.K. and Seo, E.K., 2008, 
Identification of a New Cytotoxic 
Biflavanone from Selaginella doederleinii, 
Chem. Pharm. Bull., 56(9), 1360—1361. 
Tan, W.J., Xu, J.C., Li, L., and Chen, K.L., 2009,  
Bioactive compounds of inhibiting 
xanthine oxidase from Selaginella 
labordei, Nat Prod Res., 23(4), 393-398. 
Lin, R.C., Seguin, E., Tillequin, F. and Koch, M., 
1987, New Alkaloid Glycosides from 
Selaginella doederleinii, J. Nat. Prod., 1987, 
50(3), 422–426. 
Lin, R.C., Skaltsounis, A.L., Seguin, E., Tillequin, 
F. and Koch, M., 1994, Phenolic 
Constituents of Selaginella doederleinii, 
Planta medica, 60(2), 168-170. 
Kaur, P., Shukla, S. and Gupta, S., 2008, Plant 
flavonoid apigenin inactivates Akt to 
trigger apoptosis in human prostate 
cancer: an in vitro and in vivo study, 
Carcinogenesis, 29(11), 2210-2217. 
Khan, T.H. and Sultana, S. 2006, Apigenin 
induces apoptosis in Hep G2 cells: 
possible role of TNF-alpha and IFN-
gamma, Toxicology, 217(2-3), 206-12. 
Knight, Z.A. and Shokat, K.M., 2007, Chemically 
targeting the PI3K family, Biochemical 
Society Transactions, 35(2), 245-249. 
Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. 
and Mills, G.B., 2005, Exploiting the 
PI3K/AKT Pathway for Cancer Drug 
*) Lee et al., 2008 (8) 
 
 
 
Handayani, et al., 2011 
Indones. J. Cancer Chemoprevent., 2(3), 319-324 
 
 
 
 
 
324 
Discovery, Review, Nature Reviews Drug 
Discovery, 4(12), 988-1004. 
Gulati, N., Laudet, B., Zohrabian, V.M., Murali, 
R. and Jhanwar-Uniyal, M., 2006, The 
antiproliferative effect of Quercetin in 
cancer cells is mediated via inhibition of 
the PI3K-Akt/PKB pathway, Anticancer 
Res., 26(2A), 1177-1181. 
Xavier, C.P.R., Lima, C.F., Preto, A., Seruca, R., 
Ferreira,M.F. and Wilson, C.P., 2009, 
Luteolin, quercetin and ursolic acid are 
potent inhibitors of proliferation and 
inducers of apoptosis in both KRAS and 
BRAF mutated human colorectal cancer 
cells, Cancer Letters, 281(2):162-170. 
Yoon, S., Shin, S., Lee, H., Chun, H. and Chung, 
A., 2006, Isoginkgetin inhibits tumor cell 
invasion by regulating 
phosphatidylinositol 3-kinase/Akt–
dependent matrix metalloproteinase-9 
expression, Mol Cancer Ther, 5(11), 
2666–2675. 
 
 
 
